Crinetics Pharmaceuticals, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Revenues
Revenue, net
Product revenue, net
Collaboration and license revenue
Total revenue, net
Operating expenses:
Cost of product revenue
Research and development
Selling, general and administrative
Total operating expenses
Loss from operations
Other income (expense):
Interest income
Change in fair value of derivative asset
Other expense, net
Total other income, net
Loss before income taxes
Income tax expense
Loss before equity method investment
Loss on equity method investment
Net loss
Net loss per share - basic and diluted
Weighted average shares - basic and diluted
Net loss per share:
Net loss per share - basic (in dollar per share)
Net loss per share - diluted (in dollar per share)
Weighted average shares - basic (in shares)
Weighted average shares - diluted (in shares)
Other comprehensive income (loss):
Unrealized gain (loss) on investment securities
Unrealized loss on foreign currency
Total other comprehensive income (loss)
Comprehensive loss

Comments